Evidence map›Paper›PMID 34652758›Full record

ArticleEuropean geriatric medicine2019

Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients.

Mohamed El Kassas, Reem El Sheemy, Mohamed Alboraie, Mohamed El Badry, Mohamed Naguib Wifi, Naglaa Youssef, Sameera Ezzat, Marwa Tahoon, Lobna Abdelsalam, Sara M Abdelhakam and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European geriatric medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Mohamed El Kassas *Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Reem El SheemyTropical Medicine Department, Faculty of Medicine, Minia University, Minia, Egypt.
Mohamed AlboraieInternal Medicine Department, Al-Azhar University, Cairo, Egypt.
Mohamed El BadryTropical Medicine and Gastroenterology Department, Faculty of Medicine, Aswan University, Aswan, Egypt.
Mohamed Naguib WifiInternal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Naglaa YoussefMedical-Surgical Nursing Department, Faculty of Nursing, Cairo University, Cairo, Egypt.
Sameera EzzatEpidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Shebin El Kom, Egypt.
Marwa TahoonEpidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Shebin El Kom, Egypt.
Lobna AbdelsalamGenome Unit, Faculty of Medicine, Cairo University, Cairo, Egypt.
Sara M AbdelhakamDepartment of Tropical Medicine, Faculty of Medicine, Ain Shams University, Khalifa El-Maamon St., Abbassia, Cairo, 11341, Egypt. saratropical@yahoo.com.
Zainab Ali-Eldin *Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Cairo University · EGAin Shams University · EGMenoufia University · EGAl-Azhar University · EGAswan University · EGHelwan University · EGMinia University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimOld people with chronic hepatitis C (HCV) were considered a difficult-to-treat category with more frequent adverse events until recently. Interferon-free direct-acting antivirals (DAAs) improved treatment adherence and quality of life of old patients. In this study, we aimed at reporting the real-world efficacy and safety of DAAs, in addition to predictors of sustained virological response (SVR) in old chronic HCV population.

methodsThis is a prospective observational intention-to-treat analysis that included old chronic hepatitis C genotype-4 patients (> 65 years) treated in a single specialized viral hepatitis treatment center in Egypt. Treatment regimens were allocated according to national guidelines for treatment of hepatitis C. Primary outcome was undetectable HCV-RNA at 12-week post-treatment by PCR. Secondary outcomes were identification of predictors of SVR and assessment of safety related issues.

resultsOur study included 864 patients (64% females) with mean age of 67.7 ± 2.8 years. Overall SVR rate was 98.9% while SVR rates for sofosbuvir/daclatasvir/ribavirin, paritaprevir/ombitasvir/ritonavir/ribavirin, sofosbuvir/daclatasvir, sofosbuvir/ledipasvir/ribavirin, sofosbuvir/simeprevir/daclatasvir/ribavirin, sofosbuvir/simeprevir, interferon/sofosbuvir/ribavirin and sofosbuvir/ribavirin were 100%, 100%, 100%, 100%, 100%, 99.3%, 98% and 94.2%, respectively. DAAs were well tolerated. None of the patients discontinued the treatment due to adverse effects. Higher albumin, higher platelet count, lower bilirubin and lower stage of fibrosis were among predictors of favourable response.

conclusionDifferent DAAs regimens were safe and effective in old Egyptian patients with chronic HCV.

Indexed as

Direct-acting antiviralsEgyptHCVOld

Identifiers

PMID34652758
OpenAlexW2911919097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.